Empirical radioiodine therapy as diagnostic strategy to identify occult lesions in thyroid cancer patients with elevated thyroglobulin levels but no structurally identifiable disease

Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-28.

https://doi.org/10.1016/0002-9343(94)90321-2

Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al., American Thyroid Association (ATA) Guidelines Taskforce on thyroid nodules and differentiated thyroid cancer. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.

https://doi.org/10.1089/thy.2009.0110

Kloos RT, Mazzaferri EL. A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047-57.

https://doi.org/10.1210/jc.2005-0492

Mazzaferri EL, Robbins RJ, Braverman LE, Pacini F, Haugen B, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-41.

https://doi.org/10.1210/jc.2002-021702

Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocrine-related cancer. 2013;20:R141-54.

https://doi.org/10.1530/ERC-13-0066

Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:3668-73.

https://doi.org/10.1210/jc.2002-021925

Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3590-4.

https://doi.org/10.1210/jc.2007-0444

Tuttle RM. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14:764-74.

https://doi.org/10.4158/EP.14.6.764

Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole-body scan: comparison of patients treated with high I-131 activities versus untreated patients. J Clin Endocrinol Metab. 2001;86: 4092-7.

https://doi.org/10.1210/jcem.86.9.7831

Baudin E, Cao CD, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107-11.

https://doi.org/10.1210/jc.2002-021365

Robbins R, Schlumberger M. The evolving role of I-131 for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46:28S-37S.

Ma C, Xie J, Kuang A. Is empiric I-131 therapy justified for patients with positive thyroglobulin and negative I-131 wholebody scanning results? J Nucl Med. 2005;46:1164-70.

Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest. 1999;22 suppl:3-7.

Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases of differentiated thyroid carcinoma. J Nucl Med. 1996;37:598-605.

Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993;34:1626-31.

Kabasakal L, Selcuk NA, Shafipour H, Ozmen O, Onsel C, Uslu I. Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging. 2004;31:1500-4.

https://doi.org/10.1007/s00259-004-1516-y

Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tgpositive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521-6.

https://doi.org/10.1210/jcem.87.4.8373

Garavito G, Llamas-Olier A, Cadena E, De los Reyes A, Hurtado G, Rojas L, et al. Manejo multidisciplinario del cáncer diferenciado de tiroides en el Instituto Nacional de Cancerología. Rev Colomb Cancerol. 2010;14:65-77.

https://doi.org/10.1016/S0123-9015(10)70100-1

Vaisman F, Tala H, Grewal R, Tuttle RM. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid. 2011;21: 1317-22.

https://doi.org/10.1089/thy.2011.0232

Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341-9.

https://doi.org/10.1089/thy.2010.0178

Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999;9:435-41.

https://doi.org/10.1089/thy.1999.9.435

Zanotti-Fregonara P, Keller I, Calzada-Nocaudie M, Al-Nahhas A, Devaux JY, Grassetto G, et al. Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients: are there sources of benign secretion? A speculative short review. Nucl Med Commun. 2010;31:1054-8.

https://doi.org/10.1097/MNM.0b013e328340e717

Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid. 2002;12:707-11.

https://doi.org/10.1089/105072502760258686

Savin S, Cvejic, Mijatovic L, Simonovic S. Measuring thyrglobulin concentrations in patients with differentiated thyroid carcinoma. J Medical Biochem. 2010;29:243-53.

https://doi.org/10.2478/v10011-010-0029-4

Schlumberger M, Baudin E. Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol. 1998;138:249-52.

https://doi.org/10.1530/eje.0.1380249

Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.

https://doi.org/10.1056/NEJM199801293380506

Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489-94.

https://doi.org/10.1001/archsurg.141.5.489

Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946-54.

https://doi.org/10.1016/S0039-6060(03)00424-0

Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer. 2003;97:90-6.

https://doi.org/10.1002/cncr.11031

Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, et al. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging. 2008;35:950-7.

https://doi.org/10.1007/s00259-007-0634-8

Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging. 2007;34:487-95.

https://doi.org/10.1007/s00259-006-0276-2

Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqui S, Abdal Salam S, Shoukri M. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest. 2005;28:540-6.

https://doi.org/10.1007/BF03347243

Yim JH, Kim EY, Kim WB, Kim WG, Kim TY, Ryu JS, et al. Longterm consequence of elevated thyroglobulin in differentiated thyroid cancer. Thyroid. 2013;23:58-63.

https://doi.org/10.1089/thy.2011.0487

Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-63.

https://doi.org/10.1210/jcem.86.4.7407

Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50: 18-23.

https://doi.org/10.2967/jnumed.108.052746

Glazer DI, Brown RKJ, Wong KK, Savas H, Gross MD, Avram AM. SPECT/CT evaluation of unusual physiologic radioiodine biodistributions: pearls and pitfalls in image interpretation. Radiographics. 2013;33:397-418.

https://doi.org/10.1148/rg.332125051

Spanu A, Solinas ME, Chessa F, Sanna D, Nuvoli S, Madeddu G. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50:184-90.

https://doi.org/10.2967/jnumed.108.056572

Avram A. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med. 2012;53:754-64.

Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7: 273-6.

https://doi.org/10.1089/thy.1997.7.273

Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I wholebody scanning. J Nucl Med. 2005;46:1473-80.

Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221-6.

Bertagna F, Biasiotto G, Orlando E, Bosio G, Giubbinni R. Role of 18 F-fluordeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Jpn J Radiol. 2010;28:629-36.

https://doi.org/10.1007/s11604-010-0488-z

Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, et al. Resistance of (18F)-fluordeoxygliucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11:1169-75.

https://doi.org/10.1089/10507250152741028

Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-8.

Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-84.

https://doi.org/10.1097/SLA.0b013e31814697d9

Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNM practice guideline for therapy of thyroid disease with I-131 3.0. J Nucl Med. 2012;53:1-19.

https://doi.org/10.2967/jnumed.112.105148

Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factor for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723-9.

https://doi.org/10.1210/jc.2005-0285

Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a metaanalysis involving 3947 patients. J Clin Endocrinol Metab. 2012;97:2754-63.

https://doi.org/10.1210/jc.2012-1533

Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683-9.

https://doi.org/10.2967/jnumed.110.081059

Spencer CA, Wang CC. Thyroglobulin measurement: techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am. 1995;24:841-63.

https://doi.org/10.1016/S0889-8529(18)30023-9

Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707-16.

https://doi.org/10.1089/thy.2010.0355

Mazzaferri E. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46:1079-88.

Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953-9.

https://doi.org/10.1097/RLU.0b013e31825b2057

Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46:28S-37S.